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 Background: Cardiac magnetic resonance (CMR) is increasingly used to assess heart diseases. Relevant non-cardiac diseas-
es may also be incidentally found on CMR images. The aim of this study was to determine the prevalence and 
nature of incidental extra-cardiac findings (IEF) and their clinical impact in non-selected patients referred for 
CMR.
 Material/Methods: MR images of 762 consecutive patients (515 men, age: 56±18 years) referred for CMR were prospectively inter-
preted by 2 radiologists blinded for any previous imaging study. IEFs were classified as major when requiring 
treatment, follow-up, or further investigation. Clinical follow-up was performed by checking hospital informa-
tion records and by calling referring physicians. The 2 endpoints were: 1) non-cardiac death and new treatment 
related to major IEFs, and 2) hospitalization related to major IEFs during follow-up.
 Results: Major IEFs were proven in 129 patients (18.6% of the study population), 14% of those being unknown before 
CMR. During 15±6 month follow-up, treatment of confirmed major IEFs was initiated in 1.4%, and no non-car-
diac deaths occurred. Hospitalization occurred in 8 patients (1.0% of the study population) with confirmed ma-
jor IEFs and none occurred in the remaining 110 patients with unconfirmed/unexplored major IEFs (p<0.001).
 Conclusions: Screening for major IEFs in a population referred for routine CMR changed management in 1.4% of patients. 
Major IEFs unknown before CMR but without further exploration, however, carried a favorable prognosis over 
a follow-up period of 15 months.
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Background
Cardiac magnetic resonance (CMR) is a highly reproducible 
method performed to assess myocardial morphology as well 
as global and regional heart function. It also provides rele-
vant information regarding tissue characteristics such as via-
bility, myocardial perfusion, storage diseases, and inflamma-
tion. CMR is thus increasingly used in daily practice [1,2] and 
demonstrated great efficacy in detecting coronary artery dis-
ease (CAD) as compared to stress echocardiography [3,4] or 
myocardial scintigraphy [5–7]. Therefore, CMR is recommend-
ed in current guidelines for the work-up of CAD [8] and heart 
failure [9]. In CMR examinations a scrupulous reading of non-
cardiac structures may also detect relevant non-cardiac dis-
eases. Indeed, some incidental extra-cardiac findings (IEFs) 
such as pneumonitis, pleurisy, pulmonary embolism or aortic 
diseases may also mimic cardiac symptoms. While substan-
tial data exist on the prevalence of IEFs on CMR examinations 
[10–17], it is less clear to what extent these IEFs influence 
patient management and outcome. Reported prevalences of 
major and minor IEFs detected in CMR examinations ranged 
between 3–27% and 5–31%, respectively, depending on wheth-
er great vessels pathologies were considered [10–12,16,17]. 
Wyttenbach et al. [17] reported a prevalence of 34% for po-
tentially significant IEFs, while Atalay et al. [10] found a prev-
alence of 10% for significant major IEFs when excluding the 
pathologies of the great vessels.
In view of the paucity of outcome data, this study was per-
formed in a large population undergoing a CMR examination 
to determine the prevalence of major and minor IEFs, and in 
particular to assess the impact of these findings on patient 
management and outcome during the first year after CMR.
Material and Methods
Study protocol and CMR imaging
Seven hundred sixty-two patients referred to the Cardiac 
Magnetic Resonance Center of our University Hospital be-
tween August 2011 and September 2013 for clinically indicat-
ed CMR were consecutively included. The Institutional Review 
Board approved the study. All patients accepted participation 
and gave their written informed consent before CMR for the 
use of imaging results for clinical research purpose and for a 
follow-up phone call. All patients had a single CMR examina-
tion. For every patient, common cardiovascular risk factors and 
coronary angiography results were recorded.
All CMR studies were performed on a 1.5 Tesla (n=425, 
MAGNETOM Aera, Siemens Medical Imaging, Erlangen, 
Germany) or 3 Tesla (n=337, MAGNETOM Verio or Skyra, 
Siemens Medical Imaging, Erlangen, Germany) equipment. All 
sequences were part of the daily CMR protocol of our insti-
tution. Imaging protocols included multi-planar localizers (TR 
290 ms, TR 1.13 ms, matrix 256×256, 8-mm slice thickness) 
and an axial T2-weighted half-Fourier single-shot turbo-spin 
echo (HASTE) (TR 750 ms, TE 40 ms, matrix 368×512, 8-mm 
slice thickness, field-of-view 350 mm), followed by short-axis 
(TR 49 ms, TE 1.3 ms, matrix 208×256, 8-mm slice thickness) 
and long-axis cine acquisitions (TR 37 ms, TE 1.3 ms, matrix 
168×208, 6-mm slice thickness) for assessment of LV and RV 
morphology and function. After injection of contrast medium 
(0.2 mmol/kg IV Gadovist®, Bayer Healthcare, Germany) axial, 
coronal, and sagittal gadolinium enhanced fat-sat T1-weighted 
3D-volumetric interpolated breath-hold acquisitions (VIBE) 
(TR 4.6 ms, TE 2.3 ms, matrix 260×320, slice thickness 3 mm, 
field-of-view 350 mm) were performed for extra-cardiac struc-
tures analysis.
CMR analysis
All sequences, including axial T2-weighted (HASTE) and gado-
linium enhanced T1-weighted axial, sagittal, and coronal imag-
es (VIBE), were prospectively reviewed in consensus by 2 expe-
rienced thoracic radiologists (XB, CB-A) who were blinded for 
any previous imaging study and the patients’ previous history.
Incidental IEFs were categorized into major and minor find-
ings. Major IEFs were defined as findings requiring treatment 
or follow-up, and findings of unclear nature needing further 
investigation. Minor IEFs were defined as findings considered 
as benign disease without the need for complementary exam-
ination nor follow-up or treatment. Imaging examinations per-
formed previously to CMR and available on our institutional 
picture archiving and communications system were secondari-
ly analyzed to classify IEFs as known or unknown. Additional 
imaging studies such as CT, ultrasonography, or X-ray mam-
mography were suggested to the patient’s referring physician 
to confirm or exclude unknown major IEFs. Proven major IEFs 
included major IEFs known before CMR and major IEFs un-
known before CMR but confirmed by subsequent investigations.
Follow-up of patients with unknown major IEFs
Clinical follow-up of patients with unknown major IEFs on CMR 
was subsequently performed from October 2013 to December 
2013. For every patient, any new treatment related to these 
major IEFs was searched in the hospital information system 
and recorded. Major IEF-related non-cardiac deaths and hos-
pitalizations related to major IEF were also registered. When 
data were not available in the patient charts, information was 
sought using a structured phone interview with the referring 
physician. The primary end-point during follow-up consisted of 
the composite of non-cardiac death related to major IEFs and 
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initiation of a treatment of major IEFs. The secondary end-point 
was hospitalizations related to major IEFs during follow-up.
Statistics
All statistics were performed with Stata 13.0 software (Stata 
College, Texas, USA). Continuous variables are presented as 
mean ±SD. Categorical variables are reported as percentag-
es. The prevalence of major IEFs was defined as the number 
of patients with major IEFs divided by the number of includ-
ed patients. Taking into account all patients with proven ma-
jor IEFs (patients with previously known and previously un-
known but confirmed major IEFs), logistic regression analysis 
was performed to assess the relation between major IEF and 
sex, diabetes, hypertension, dyslipidemia, obesity, smoking, 
CAD (proven by coronary angiography), symptoms or type of 
equipment (1.5 vs. 3-Tesla scanner). Age comparison between 
patients with or without major IEFs was assessed by Student’s 
t-test. A p-value<0.05 was considered as statistically significant.
Results
Patient population
Between August 2011 and September 2013, 762 patients 
(mean age 56±18 y, range: 1–88 years) referred to our CMR 
center were included and consecutively read by 2 observers. 
The female-to-male ratio was 1: 2.1 (247 women: 515 men). 
One hundred five (18%) patients had diabetes, 301 (40%) had 
hypertension, 263 (35%) had dyslipidemia, 182 (24%) smoked, 
92 (12%) had family history of CAD, and 222 patients (29%) 
had CAD proven by coronary angiography. Four hundred and 
eleven (54%) patients were asymptomatic.
Extra-cardiac findings
Of 762 patients, 440 (57.7%) had a total of 735 IEFs, 322 
patients having no IEF (Table 1). Among all IEFs, 368/735 
(50.1%) were categorized as unknown. Liver (138/735), kidney 
Abnormalities All (n) Unknown (n) Explored (n) Confirmed (n)
Thyroid or thymic mass/nodule 11 5 1 0
Mediastinal adenopathy 39 19 6 2
Aortic dilatation/dissection/coarctation 63 21 8 7
Main pulmonary trunk dilatation 11 4 1 0
Esophageal wall thickening 4 1 0 0
Major parenchymal lung lesion 44 21 13 2
Pulmonary embolism/angiosarcoma 15 13 8 5
Pleural effusion with thickening/pleural nodule/chest wall 
abnormality
3 0 0 0
Breast nodule/mass 25 19 9 0
Axillary adenopathy 2 0 0 0
Hepatic mass/dilated biliary tree/cirrhosis/hepatomegaly 45 31 11 3
Splenomegaly/splenic lesion 6 5 3 0
Complex renal cyst/renal tumor/dilated renal pelvis 13 9 6 2
Adrenal mass/nodule 4 4 1 0
Retroperitoneal lesion 3 2 1 0
Vertebral body lesion 15 9 3 0
Muscular lesion 1 0 0 0
Total 304 163 74 21
Table 1. Major extracardiac findings.
Dilated aorta >40 mm; Major parenchymal lung lesion: nodule >1 cm, multiple micronodules, consolidation, mass, metastasis, 
interstitial lung disease; Adenopathy >1 cm small axis.
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(109/735), and lung parenchyma (100/735) were the 3 organs 
most frequently concerned with major and minor IEFs.
Of a total of 735 IEFs, 304 IEFs in 239 patients were classi-
fied as major (Table 1). There were 183 patients with 1 major 
IEF and 56 patients with more than 1 major IEF. Of 304 major 
IEFs, 163 (54%) in 128 patients were unknown. Besides aortic 
diseases (63/304; 20.7%), the 3 structures most frequently af-
fected by major IEFs were the liver (45/304; 14.8%), the lungs 
(44/304; 14.3%), and the mediastinal lymph nodes (39/304; 
12.7%). Seventy-four unknown major IEFs were explored and 
21 were confirmed in 18 patients, the others being minor 
IEFs (Table 2). Eighty-nine (29.3%) major IEFs remained un-
explored during follow-up. Among 163 unknown major IEFs, 
21 new diagnoses were established (Figures 1 and 2), includ-
ing aortic disease in 7 patients (4.3%), pulmonary embolisms 
in 5 patients (3.1%), and tumors in 3 patients (1.9%). Overall, 
the prevalence of proven major IEFs was 18.6% (111 patients 
with known major IEFs and 18 patients with confirmed un-
known major IEFs divided by 762 patients minus 70 patients 
with unexplored major IEFs, see Figure 3), 14% (18/129) of 
them being unknown before CMR.
Patients with major IEFs were older than patients without 
(60±15 vs. 54±18 years, p<0.0001). Taking into account all pa-
tients with proven major IEFs, there was no significant relation 
between major IEFs and sex, diabetes, hypertension, dyslip-
idemia, smoking, symptoms, CAD, obesity, or type of MR im-
ager (p>0.11).
A total of 431 minor IEFs were recorded in 201 patients (preva-
lence of 26.4%). Kidneys (96/431), liver (93/431), and lung pa-
renchyma (56/431) were the 3 structures the most frequently 
concerned when considering minor and major IEFs (Table 2).
Follow-up of patients with unknown major IEFs
a) Primary end-point
The mean follow-up duration for patients with unknown major 
IEFs was 15±6 months. A total of 11 patients were treated for 
major IEFs and no death for non-cardiac reasons occurred. Thus, 
the primary end-point was observed in 1.4% of the study pop-
ulation (total n=762). Three of these 11 patients were treated 
for pathologies of the thoracic aorta and 5 patients for pulmo-
nary embolism, corresponding to 0.4% and 0.7% of the total 
study population, respectively (Figure 3). Three patients (0.4% 
of the total population) were treated for extra-thoracic major 
IEFs (renal and bladder cancer, liver cirrhosis). Specifically, in 
2 patients with thoracic aortic aneurysms, open-chest repair 
was performed and 1 patient with aortic dissection was treat-
ed by endoprosthesis placement. Anticoagulation therapy was 
Abnormalities n
Thyroid goiter/cyst 6
Mediastinal lymph node 9
Aortic ectasia/anatomical variants 18
Main pulmonary trunk prothesis 1
Hiatus hernia/oesophagitis/esophageal dilation 18
Minor parenchymal lung lesion 56
Pleural effusion without thickening 38
Breast cyst/post-surgical status/gynecomastia 9
Diaphragmatic hernia 8
Axillary benign lesion (lipoma) 1
Hepatic cyst, hemangioma 93
Splenectomy/polysplenia/splenic cyst/accessory spleen 19
Simple renal cyst 96
Vertebral body angioma/discarthropathy/Schmorl hernia 56
Benign muscular lesion 3
Total 431
Table 2. Minor extracardiac findings.
Minor parenchymal lung lesion: stripe, atelectasia, solitary micronodule, azygous lobe, post-surgical status.
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started in 5 patients with pulmonary embolism. Among 128 
patients with unknown major IEFs, only 1 patient died from 
end-stage heart failure, no deaths due to non-cardiac disease 
occurred during follow-up (Figure 3).
b) Secondary end-point
Patients’ follow-up revealed that 8 patients were hospitalized 
due to major IEFs found on CMR corresponding to 1.0% of 
the total study population (Figure 3). These 8 hospitalizations 
occurred in the 18 patients with a confirmation of major IEF 
by further investigations (CT in 16 patients, ultrasound in 2 
patients) whereas no hospitalization occurred in the remain-
ing 110 patients with major IEFs (44% vs. 0%, p<0.001), which 
were not confirmed in additional tests (n=40) or where no fur-
ther testing was performed (n=70). Hospitalizations occurred 
more frequently in patients who underwent further testing af-
ter CMR (n=58) than in cases where no further testing was per-
formed (n=70) (14% vs. 0%, respectively, p=0.001).
A B
C D E
Figure 1.  Patient with left pyelocaliceal dilation and pulmonary nodule that revealed bladder cancer. (A) Left pyelocaliceal dilation 
on fat-sat post-gadolinium T1-weighted coronal image. (B) Thickening of the left ureterovesical junction (arrow) on coronal 
unenhanced CT view. (C and D) Necrotic metastasis of the left posterobasal segment of the left lower lobe on axial fat-sat 
post-gadolinium T1-weighted and axial CT view respectively. (E) Thickening of the left ureterovesical junction (arrow) on axial 
enhanced CT view.
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Discussion
The main findings of this study can be summarized as follows: 
1) Proven major IEFs were found in 18.6% of the study pop-
ulation. These major IEFs were correlated with age but not 
with other cardiovascular risk factors and involved most fre-
quently the thoracic aorta, the lungs, the mediastinal lymph 
nodes and the liver; 2) A new treatment was installed because 
of the detection of previously unknown major IEFs in 1.4% of 
the study population, and no death from major IEFs occurred; 
3) In the 70 patients with previously unknown major IEFs on 
CMR, which were not further explored, the prognosis during 
follow-up however appeared favorable with no treatment ini-
tiated and no death for non-cardiac reasons.
Prevalence of proven major IEFs
In the current study, proven major IEFs were found in 18.6% 
of the population, which is in line with other recent studies 
that reported similar prevalences for major IEFs during CMR 
of 3–27% [10–12,16,17]. Except for the aorta, the 3 most fre-
quently involved organs presenting with major IEFs were the 
liver (14.8% of major IEFs), lung parenchyma (14.5%), and me-
diastinal lymph nodes (12.8%), as described in previous large 
studies [11,13,16]. Also, as previously published [10,13], the 
prevalence of major IEFs correlated with age in the current 
study, but not with other cardiovascular risk factors.
It is important to mention that criteria for major and minor 
IEFs were used differently in the various studies, which can 
explain differences in prevalence. Khosa et al. [14] described 
thoracic lymphadenopathy of less than 1.5 cm as benign find-
ings, while Wyttenbach et al. [17] included hiatal hernia (n=6), 
gallstones (n=8), or left superior vena cava (n=5) as signifi-
cant findings, yielding a prevalence of 23%. Atalay et al. [10] 
reported a prevalence of 15% for significant non-cardiac find-
ings but did not include aortic or main pulmonary artery dis-
ease, which may influence the prevalence, since we found that 
A
C
B
D
Figure 2.  Patient with confirmed new pulmonary embolism. (A and B) Vascular filing defect of the posterobasal segmental pulmonary 
artery of the right lower lobe (arrows) on axial fat-sat post-gadolinium T1-weighted and axial CT pulmonary angiography 
views, respectively. (C and D) Vascular filling defect of the laterobasal segmental pulmonary artery of the right lower lobe 
(arrows) on axial fat-sat post-gadolinium T1-weighted and coronal CT pulmonary angiography views, respectively.
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93/735 (12.7%) IEFs concerned these structures in our study. 
These findings clearly highlight the need for a harmonization 
of the definition of minor and major IEFs for CMR.
There are also methodological and technical variations to con-
sider when comparing the prevalences of IEFs reported in the 
literature. Hence, some authors only reported IEFs based on 
CMR report review [10,11,13], while others performed a com-
plete image analysis [12,14–17], as we did. This can signifi-
cantly influence the number of non-cardiac findings, as demon-
strated by Wyttenbach et al. [17]. Irwin et al. [13] also reported 
that there was no statistical difference in reported IEF rate be-
tween cardiology and radiology readers on separate examina-
tions. There is, however, no published data on the equality of 
performance to detect IEF between cardiologists and radiolo-
gists in a blinded fashion.
Pulmonary embolism and other lung pathologies
The most frequent extra-cardiac diagnosis was pulmonary em-
bolism, which was suspected by CMR in 15 patients. Of those, 
8 patients underwent further exploration, which confirmed the 
diagnosis in 5 patients, yielding a specificity of 63%. In our 
study, all pulmonary embolisms were diagnosed on contrast-
enhanced T1-weighted VIBE images by detecting endoluminal 
hyposignals on at least 2 orthogonal sequences in order to ex-
clude flow artifacts [18]. As no dedicated MR pulse sequences 
were used to detect pulmonary embolism and the T1-weighted 
VIBE images did not cover the entire lung parenchyma, this 
specificity is not surprising, but is rather low in comparison to 
previous findings [19–21]. Pulmonary nodules and other pa-
renchymal lung lesions were detected in 5.8% of patients, but 
diagnoses were confirmed in only 2 of 13 patients (specifici-
ty of 15%). The prevalence of major parenchymal lung lesions 
was also lower in comparison to that reported by Horton et 
al. [22] and Onuma et al. [23] in cardiac MDCT studies, mainly 
due to the lower spatial resolution of MRI. These data suggest 
that further improvements of pulse sequences are needed to 
allow for a better assessment of lung tissue and a better es-
timation of the prevalence of IEFs in lung parenchyma during 
CMR. Overall, the prognosis of the patients with major unknown 
IEFs of the lung parenchyma was good, with no need for treat-
ment and no death for extra-cardiac reasons during follow-up.
Impact of previously unknown major IEFs on patient 
management and outcome
Of the 128 patients with previously unknown major IEFs on 
CMR, treatment was initiated in 8.6% in11 patients or 1.4% 
of the screened study population. A major IEF of the thorax 
leading to a change in management was found in 8 patients 
(1.0% of the study population). In 5 patients anticoagulation 
was initiated due to the detection of pulmonary embolism con-
firmed by CT and in 3 patients the thoracic aorta was treated (2 
open chest repair, one endoprosthesis). An abdominal pathol-
ogy was found in 3 patients (1 renal cancer, 1 urinary bladder 
cancer, 1 liver cirrhosis). From the current study, we can only 
speculate on the potential benefit of the patients treated for 
Figure 3.  Patients’ IEFs flowchart. Non-
cardiac deaths, treatments and 
hospitalizations related to major IEFs 
are reported for each category. By 
convention, we used in this figure the 
small letter n when describing the 
number of patients and the capital N 
when describing the number of IEF. * 
One patient died from end stage heart 
failure.
Included patients
n=762 pts
Patients without IEF
n=322 pts
Minor IEFs
n=201 pts, N=431
Known major IEFs
n=111 pts, N=141
1st endpoint:
– death: o pts
– treatment: 11 pts
2nd endpoint:
– hospitalization: 8 pts
Patients with IEFs
n=440 pts, N=735
Major IEFs
n=239 pts, N=304
Unknown major IEFs
n=128 pts, N=163
Explored major IEFs
n=58 pts, N=74
Unexplored major IEFs
n=70 pts, N=89
Confirmed major IEFs
n=18 pts, N=21
1st endpoint:
– death: 1 pts*
– treatment: 0 pts
2nd endpoint:
– hospitalization: 0 pts
Unexplored major IEFs
n=70 pts, N=89
1st endpoint:
– death: o pts
– treatment: 0 pts
2nd endpoint:
– hospitalization: 0 pts
Unconfirmed major IEFs
n=40 pts, N=53
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peripheral pulmonary embolisms. In another 5 patients with 
this diagnosis on CMR but without any further testing or con-
firmation, no complications (no death, no treatment, no hos-
pitalization) occurred during the follow-up period after CMR.
In 2 patients (0.3% of the study population), abdominal tu-
mors were detected (kidney and urinary bladder). However, 
from these data it remains questionable whether a system-
atic reading of abdominal structures on CMR studies should 
be recommended.
As it was an observational study, confirmation or exclusion of 
majors IEFs found on CMR was not obtained in all patients. 
Whether reported major IEFs were subject to additional test-
ing was at the discretion of the referring physician. Only 45% 
of the patients with newly diagnosed major IEFs on CMR un-
derwent a further work-up and the CMR diagnosis was con-
firmed in 31% of these patients. In the remaining 110 patients, 
major IEFs were not confirmed or were not explored further. 
Interestingly, in these 110 patients, the outcome over the first 
15 months after CMR was excellent without any IEF-related 
death or treatment change, and no IEF-related hospitalization. 
These results may indicate that major IEFs, if not accompanied 
by clinically suspicious symptoms or findings that trigger fur-
ther testing, may have little or no impact on patient outcome, 
at least during the first 15 months after a CMR examination.
In summary, the presence of a previously unknown major IEF on 
CMR caused new treatment initiation in 1.4% of the study pop-
ulation and this decreased to 1% for IEF located in the thorax.
Limitations
The detection of minor and major IEFs was evaluated on all 
sequences performed in the daily CMR protocol of our insti-
tution, which includes T2-weighted HASTE and contrast-en-
hanced T1-weighted VIBE sequences. While other studies re-
ported IEFs using either scout, steady-state free precession 
(SSFP), HASTE, or T1-weighted fast spin echo images, alone or 
in combination, it remains unclear whether major IEFs detec-
tion would benefit from dedicated fast or ultrafast sequenc-
es such as contrast-enhanced T1-weighted VIBE by using fast 
gradient echo respiration-triggered or 3D-contrast-enhanced 
sequences [19,24,25] especially for the detection of pulmo-
nary embolism.
Eighty-nine unknown major IEFs remained unexplored, most 
likely because the decision to add further testing was at the 
discretion of the referring physician. With the current design of 
this study, we cannot assess what would be the impact of un-
known major IEFs if all these lesions would have been further 
explored. At least, in this population without further testing 
of major IEFs, the prognosis was favorable with no treatment 
started, no death for non-cardiac reasons and no hospitaliza-
tion related to major IEFs. The good prognosis of this patient 
subset also indicates that the presence of major IEFs per se is 
not associated with complications during follow-up. Further 
study is needed on the additional information that prompted 
treating physicians to further explore unknown major IEFs or 
information that cannot be extracted from the current data 
but would warrant further study.
We performed an early follow-up within 15±6 months. A lon-
ger follow-up period is however mandatory to evaluate the 
impact on the long term.
The detection of major IEFs modified patient management, i.e. 
it induced further testing (58 patients), additional treatment 
(11 patients) and hospitalization (8 patients). The cost for the 
acquisition of the T2-weighted and T1-weighted sequences, 
the reading of these images as well as the costs for down-
stream additional testing and treatment was not assessed in 
this study. While data exist on the cost-effectiveness of CMR for 
the work-up of CAD [26,27] a prospective study should assess 
the economic impact of the detection of major IEFs by CMR.
Conclusions
Proven major IEFs were found in 18.6% of patients undergo-
ing a routine CMR exam. The most commonly involved organs 
were the thoracic aorta, the liver, lungs, and the mediastinal 
lymph nodes. Pulmonary embolism accounted for 3.1% of un-
known major IEF. Screening for major IEFs in a population re-
ferred for routine CMR changed management in 1.4% of pa-
tients, and in 1% in patients with unknown major IEF of the 
thorax. Major IEFs unknown before CMR but without further 
exploration however carried a favorable prognosis over a fol-
low-up period of 15 months. Longer follow-up is needed to 
determine whether these major IEFs may influence long term 
patient survival.
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